Insiders CureVac N.V.

Equities

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
3.13 ^USD	+13.00%		+34.33%	-25.65%

May. 02	CUREVAC : A missed opportunity
Apr. 26	UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	MT

CureVac Hires New Chief Business Officer	Apr. 24	MT
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024	Apr. 24	CI
CureVac's Chief Scientific Officer Steps Down	23-07-14	MT
CureVac N.V. Announces Executive Changes	23-07-14	CI
CureVac N.V. Appoints Michael Brosnan to Supervisory Board	23-06-20	CI
Curevac N.V. Approves the Appointment of Alexander Zehnder and Myriam Mendila as Managing Directors	23-03-29	CI
CureVac's New Chief Development Officer Assumes Office	23-02-01	MT
CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer	23-02-01	CI
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®	23-01-31	EQ
CureVac CEO to Depart in March; Sanofi Executive Named Successor	23-01-09	MT
CureVac Chief Executive Franz-Werner Haas to Step Down; Alexander Zehnder Named Successor	23-01-09	MT
CureVac N.V. Announces CEO Changes	23-01-09	CI
CureVac Announces Executive Changes	22-08-18	CI
CureVac N.V. Announces Board Changes	22-06-22	CI
Nykode Therapeutics Names CureVac Exec As New Chief Development Officer	22-06-13	MT
Novartis Exec To Join CureVac As Chief Development Officer	22-06-09	MT
CureVac N.V. Announces Changes of CDO	22-06-07	CI
CureVac Technology Chief Mariola Fotin-Mleczek to Step Down	22-01-18	MT
CureVac Announces Resignation of Mariola Fotin-Mleczek as Chief Technology Officer	22-01-17	CI
GSK names Pfizer scientist Dormitzer as vaccines R&D head	21-11-30	RE

No results for this search

CUREVAC : A missed opportunity

May 02, 2024 at 05:42 pm EDT